Maroeska Rovers, Professor of Evidence Based Surgery, will receive a Vici research grant of 1.5 million euros from NWO (Netherlands Organisation for Scientific Research).Over the next five years, the researchers can use this money to perform their research and build their own research groups. The Vici grant is one of the largest individual scientific prizes in the Netherlands. This year, the NWO awarded 35 Vici grants in total.
Maroeska Rovers is Professor of Evidence-based Surgery at Radboud university medical center, within the theme of Urological cancers. It is her ambition to contribute to the development of effective, affordable, and valuable surgical innovations.
Rovers will use her Vici grant to perform research with the aim of developing better methods to evaluate surgical innovations as early as possible. Currently, this evaluation takes place when these innovations have largely been developed and marketed. Up to half of the innovations do not add any value which results in a waste of healthcare costs in Europe. According to Rovers, new medical tools should already be evaluated for added value for patients as early as the very first concept. She intends to develop, test, and validate methods for this.
Related news items
Step-up approach vs open necrosectomy for necrotizing pancreatitis18 April 2019
Another publication of the successful Dutch collaborative group on pancreatitis research with substantial contribution from Radboudumc researchers, Harry van Goor and Kees van Laarhoven.read more
Prophylactic antibiotics reduce hospitalisations and cost in head and neck cancer patients18 April 2019
In European journal of cancer Janneke Ham and colleagues showed that prophylactic antibiotics in locally advanced head and neck cancer patients treated with chemoradiotherapy did not reduce the incidence of (aspiration) pneumonias, but did reduce hospitalisations and tended to be cost-effective.read more
Nontuberculous mycobacteria and fungal co-infections Bonnie and Clyde?18 April 2019
In The European respiratory journal Jakko van Ingen and Sanne Zweijpfenning showed that 40% of patients diagnosed with nontuberculous mycobacterial pulmonary disease also meet diagnostic criteria for chronic pulmonary aspergillosis.read more
ESCMID award for groundbreaking studies on NTM disease18 April 2019
Jakko van Ingen received the ESCMID Young Investigator Award for his groundbreaking work on nontuberculous mycobacterial disease.read more